ACHV vs. TKNO, VNRX, ABIO, QIPT, ALIM, BDSX, CLLS, MDWD, GLSI, and GALT
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Alpha Teknova (TKNO), VolitionRx (VNRX), ARCA biopharma (ABIO), Quipt Home Medical (QIPT), Alimera Sciences (ALIM), Biodesix (BDSX), Cellectis (CLLS), MediWound (MDWD), Greenwich LifeSciences (GLSI), and Galectin Therapeutics (GALT). These companies are all part of the "medical" sector.
Alpha Teknova (NASDAQ:TKNO) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
Alpha Teknova presently has a consensus price target of $15.00, indicating a potential upside of 653.77%. Achieve Life Sciences has a consensus price target of $14.00, indicating a potential upside of 186.89%. Given Achieve Life Sciences' higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Achieve Life Sciences.
In the previous week, Achieve Life Sciences had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 13 mentions for Achieve Life Sciences and 10 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.86 beat Achieve Life Sciences' score of 0.23 indicating that Achieve Life Sciences is being referred to more favorably in the news media.
Achieve Life Sciences received 323 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 70.21% of users gave Achieve Life Sciences an outperform vote while only 33.33% of users gave Alpha Teknova an outperform vote.
13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Achieve Life Sciences has a net margin of 0.00% compared to Achieve Life Sciences' net margin of -97.85%. Achieve Life Sciences' return on equity of -38.24% beat Alpha Teknova's return on equity.
Achieve Life Sciences has lower revenue, but higher earnings than Alpha Teknova. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Summary
Achieve Life Sciences beats Alpha Teknova on 10 of the 17 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
